bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) and Wellgistics Health (NASDAQ:MEDS – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.
Volatility and Risk
bioAffinity Technologies has a beta of -1.25, suggesting that its stock price is 225% less volatile than the S&P 500. Comparatively, Wellgistics Health has a beta of -3.51, suggesting that its stock price is 451% less volatile than the S&P 500.
Valuation & Earnings
This table compares bioAffinity Technologies and Wellgistics Health”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| bioAffinity Technologies | $5.85 million | 0.37 | -$14.91 million | ($109.45) | -0.03 |
| Wellgistics Health | $23.34 million | 0.37 | -$101.28 million | ($46.13) | -0.06 |
bioAffinity Technologies has higher earnings, but lower revenue than Wellgistics Health. Wellgistics Health is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares bioAffinity Technologies and Wellgistics Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| bioAffinity Technologies | -257.30% | -220.52% | -136.76% |
| Wellgistics Health | -1,100.16% | N/A | -171.81% |
Analyst Ratings
This is a summary of recent recommendations and price targets for bioAffinity Technologies and Wellgistics Health, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| bioAffinity Technologies | 1 | 0 | 0 | 0 | 1.00 |
| Wellgistics Health | 1 | 0 | 0 | 0 | 1.00 |
Insider and Institutional Ownership
1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 5.7% of Wellgistics Health shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by insiders. Comparatively, 27.0% of Wellgistics Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
bioAffinity Technologies beats Wellgistics Health on 6 of the 11 factors compared between the two stocks.
About bioAffinity Technologies
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
About Wellgistics Health
Founded in 2022, Wellgistics Health is a holding company for various existing and planned strategic businesses centered around pharmaceuticals and healthcare services. As a micro health ecosystem, our portfolio of companies consists of a pharmacy, wholesale operations, and a technology division with a novel platform for hub and clinical services. We are focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. In January 2023 and May 2023, Wellgistics Health entered into separate definitive agreements with the owners of Wood Sage and Wellgistics LLC, respectively, whereby Wellgistics Health would acquire all of the respective outstanding membership interests of Wood Sage and Wellgistics LLC. In June 2024, Wellgistics Health and Wood Sage entered into an amended and revised definitive agreement and closed on the Wood Sage Acquisition, thereby making Wood Sage a wholly owned subsidiary of Wellgistics Health. In connection with the Wood Sage Acquisition, Wellgistics Health acquired Wood Sage’s two operating subsidiaries, APS—a pharmaceutical technology hub—and CSP—a retail community specialty pharmacy. On August 30, 2024, Wellgistics Health closed on the Wellgistics Acquisition, thereby making Wellgistics LLC—a company focused on wholesale operations including the distribution and fulfillment of certain pharmaceutical medications to a network of independent pharmacies meant to improve market access to and patient outcomes regarding the medications—a wholly owned subsidiary of Wellgistics Health. As such, Wellgistics Health currently exists as a holding company with Wood Sage as a directly held intermediate holding company subsidiary, APS and CSP as indirect operating subsidiaries, and Wellgistics LLC as a direct operating subsidiary. On October 4, 2024, the Company changed its corporate name to “Wellgistics Health, Inc.” by filing a duly authorized Certificate of Amendment to its Certificate of Incorporation. Despite that Wellgistics Health only recently closed the Wood Sage Acquisition and the Wellgistics Acquisition during 2024, the three companies have shared common office space, comarketed solutions to the marketplace, and leveraged financial and back-office support prior to June 2024. As such, Wellgistics Health’s management believes that its close business relationships have and will continue to limit the need for post-closing integration. The mailing address of our principal executive office is 3000 Bayport Drive, Suite 950 Tampa, FL.
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
